Patents by Inventor Paul Bessette

Paul Bessette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10526560
    Abstract: A novel method of preparing metal assemblies for long term storage and instant readiness for use, utilizing a light oil mixture or grease mixture incorporating functionalized and molecularly neutral PFPE fluid and a fluorosolvent.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: January 7, 2020
    Inventors: Benjamin Clarke, Paul Bessette
  • Publication number: 20190106488
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: September 18, 2018
    Publication date: April 11, 2019
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Patent number: 10138298
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: November 27, 2018
    Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer Inc.
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20170114130
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 27, 2017
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20170081397
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 23, 2017
    Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Publication number: 20070099247
    Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.
    Type: Application
    Filed: December 19, 2006
    Publication date: May 3, 2007
    Inventors: Patrick Daugherty, Paul Bessette, Jeffrey Rice
  • Publication number: 20060030022
    Abstract: The invention provides composition and methods for producing proteins of interest which comprise at least one disulfide bond, include proteins which in their mature form do not contain disulfide bonds, but whose precursor molecule contained at least one disulfide bond. The methods employ a host cell modified to more efficiently produce properly folded disulfide bond containing proteins. The host cells generally contain a mutation in one or more reductase genes, and can be further genetically modified to increase their growth rate, and are further optionally modified to increase the expression of a catalyst of disulfide bond formation. Host cells, methods for using such to produce proteins of interest, proteins of interest produced by these methods are within the scope of the invention.
    Type: Application
    Filed: February 16, 2005
    Publication date: February 9, 2006
    Inventors: Jonathan Beckwith, Fredrik Aslund, Paul Bessette, George Georgiou, Daniel Ritz, Jackie Lim
  • Publication number: 20050196406
    Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.
    Type: Application
    Filed: August 18, 2004
    Publication date: September 8, 2005
    Inventors: Patrick Daugherty, Paul Bessette, Jeffrey Rice
  • Patent number: 6083715
    Abstract: Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: July 4, 2000
    Assignees: Board of Regents, The University of Texas System, Genentech, Inc.
    Inventors: George Georgiou, Ji Oiu, Paul Bessette, James Swartz